Cancer Research and Molecular Medicine – Dr. Antonio Giordano

by David Lemberg on December 9, 2009

in Cancer Research and Treatment, Genetics and Genomic Medicine, Lifestyle Medicine, Women's Health

Download PodcastClick the icon to play the podcast

Dr. Antonio Giordano is Director, Sbarro Institute for Cancer Research and Molecular Medicine; Director, Center of Biotechnology, Temple University’s College of Science and Technology; and President and Chairman of the Board, Sbarro Health Research Organization.

In 1993, Dr. Giordano founded the Sbarro Institute for Cancer Research and Molecular Medicine with the generous help of Mario Sbarro, president of Sbarro, Inc., an internationally successful restaurant chain. In 2002, the Institute forged an exciting alliance with Temple University, forming the Sbarro Health Research Organization.

At the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, promising researchers from around the globe pursue groundbreaking research in the molecular workings of cancer and other devastating diseases. The agreement with Temple was renewed in 2005, with the addition of two new research programs in molecular therapeutics and the study of the connections between obesity and cancer.

Dr. Giordano has been an internationally recognized researcher specializing in the genetics of cancer and gene therapy for 20 years. He has published 270 papers on his work in the fields of cell cycles, gene therapy and the genetics of cancer, and serves on the editorial boards of a number of professional journals.

In our 3-8-07 conversatin, Dr. Giordano discusses

  • His important discoveries, Rb2/p130, Cyclin A, and Cdk9 and Cdk10, and their role in the battle against cancer
  • The strong commitment at the Sbarro Institute to mentor young researchers
  • Research activities at the University of Siena in Italy
  • New developments in cancer research
Share on Social Media Sites
  • Twitter
  • StumbleUpon
  • Google Bookmarks
  • Digg
  • Facebook
  • LinkedIn
  • del.icio.us
  • FriendFeed
  • Technorati
  • Print

Comments on this entry are closed.